1582P - Pain and Bowel Function Evolution, in Cancer Patients Treated with Strong Opioids at the First Time that they Report Moderate-Severe Pain. C2 Study

Abstract

ABSTRACT Introduction and objectives Opioids remain the cornerstone of analgesic treatment for cancer patients, but gastrointestinal side effects have a great impact on their quality of life. The aim of this analysis was to evaluate the use of strong opioids in these patients, and if oxycodone/naloxone combination provides benefits in terms of analgesia, without compromising bowel function. Material and methodology Interim analysis of an observational multicentre study, in which patients reporting moderate-severe pain, at 1st time in the oncology services, were treated following investigator criteria. We present results of the patients treated with strong opioids during 1 month (N= 298). Results Baseline characteristics: 65% male, mean ± SD age: 66 ± 13 years (27% ≥ 75 years old), ECOG 1: 54%; receiving chemotherapy 64% and radiotherapy 41%. Main location of the primary tumor: lung (28%), colon/rectum (12%), head and neck (11%). Metastatic cancer: 79%; 67% of patients reported pain secondary to metastases. Comparison between patients treated with oxycodone/naloxone (n= 217) with those treated with other strong opioids (n= 81) showed a good pain control in both groups (NRS0-10-2.7 and -2.2 points respectively, p = 0,08). It was confirmed a significant improvement of bowel function ( Conclusions Clinical practice confirms significant improvements in pain relief in cancer patients reporting moderate pain at the first time in the oncology services, and treated with strong opioids. But patients treated with oxycodone/naloxone improve their bowel function, unlike those treated with other strong opioids. Disclosure All authors have declared no conflicts of interest.